drugset / Trial / NCT04408261
BuqitongluO Granule for Qi Deficiency and Blood Stasis Syndrome
Phase 2
Unknown
432 enrolled
Dongzhimen Hospital, Beijing
Affiliated Hospital of Changchun University of Chinese Medicine · collabAffiliated Hospital of Shandong University of Traditional Chinese Medicine · collabBeijing Chuanglikechuang Medical Technology Development Co., Ltd. · collabChengdu University of Traditional Chinese Medicine · collabFirst Affiliated Hospital of Guangxi Medical University · collabFirst Affiliated Hospital of Heilongjiang Chinese Medicine University · collabHunan Academy of Traditional Chinese Medicine Affiliated Hospital · collabJiangbin Hospital of Guangxi Zhuang Autonomous Region · collabRizhao Hospital of Traditional Chinese Medicine · collabSecond Affiliated Hospital of Heilongjiang University of Chinese Medicine · collabShaanxi Buchang Pharmaceuticals Co., Ltd. · collabShanghai Youningwei Biotechnology Co., Ltd. · collabThe First Clinical Hospital of Jilin Academy of Traditional Chinese Medicine · collabThe Second Affiliated Hospital of Hunan University of Traditional Chinese Medicine · collabThe Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine · collabWuhan Third Hospital · collabWuhan Zhizhi Medical Technology Co., Ltd. · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The main purpose of this trial is to evaluate the efficacy and safety of Buqitongluo Granule in treating qi deficiency and blood stasis syndrome, and explore the effect of the improvement of qi deficiency and blood stasis syndrome on the prognosis of diseases.
Timeline
- Start
- 2020-07-22
- Primary completion
- 2022-12
- Completion
- 2022-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Buqitongluo Granule | Traditional medicine (herbal / TCM) | 10 g | Oral |